Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2040-1124 (Electronic) Linking ISSN: 20401116 NLM ISO Abbreviation: J Diabetes Investig Subsets: MEDLINE
    • Publication Information:
      Original Publication: Tokyo : Asian Association for the Study of Diabetes and Blackwell Pub. Asia
    • Subject Terms:
      Biomarkers/*analysis ; Cardiovascular Diseases/*prevention & control ; Diabetes Mellitus, Type 2/*drug therapy ; Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage ; Hypoglycemic Agents/*administration & dosage ; Sodium-Glucose Transporter 2 Inhibitors/*administration & dosage; Blood Glucose/analysis ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/pathology ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/pathology ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Female ; Follow-Up Studies ; Glycated Hemoglobin/analysis ; Humans ; Hypoglycemic Agents/adverse effects ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Risk Factors ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects
    • Abstract:
      There are limited data on cardiovascular efficacy and safety of type 2 diabetes therapies in Japan, where treatments are characterized by lower metformin use and higher dipeptidyl peptidase-4 inhibitor (DPP4i) use versus other countries. We investigated the cardiovascular outcomes in Japanese patients with type 2 diabetes initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) matched 1:1 to patients initiating other glucose-lowering drugs (33,890 patients/group) or DPP4i (9,876 patients/group). SGLT2i initiation was associated with lower risks (hazard ratio of in-hospital death [death] 0.56, 95% confidence interval [CI] 0.47-0.67; hospitalization for heart failure 0.75, 95% CI 0.64-0.89; composite of hospitalization for heart failure or death 0.65, 95% CI 0.58-0.74 and stroke 0.66, 95% CI 0.52-0.84 versus other glucose-lowering drugs and lower risks of death 0.52, 95% CI 0.36-0.73) and composite of hospitalization for heart failure or death (0.65, 95% CI 0.51-0.83) versus DPP4i. In conclusion, SGLT2i initiators had lower risks of cardiovascular events versus other glucose-lowering drug initiators and, uniquely, versus DPP4i initiators in Japanese real-world practice.
      (© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)
    • References:
      J Diabetes Investig. 2021 Jan;12(1):67-73. (PMID: 32530554)
      J Diabetes Investig. 2016 Apr;7 Suppl 1:102-9. (PMID: 27186364)
      Circulation. 2020 Apr 14;141(15):1227-1234. (PMID: 31983236)
      J Diabetes Investig. 2018 Mar 26;:. (PMID: 29582574)
      Circulation. 2008 Dec 16;118(25):2702-9. (PMID: 19106393)
      Circ J. 2008 Mar;72(3):489-91. (PMID: 18296852)
      Diabetologia. 2013 Apr;56(4):696-708. (PMID: 23344728)
      JAMA. 2019 Jan 1;321(1):69-79. (PMID: 30418475)
      Mayo Clin Proc. 2011 Oct;86(10):960-7. (PMID: 21964173)
      N Engl J Med. 2015 Jul 16;373(3):232-42. (PMID: 26052984)
      Diabetes Obes Metab. 2019 May;21(5):1237-1250. (PMID: 30697905)
      Diabetes Care. 2003 Feb;26(2):360-6. (PMID: 12547863)
      Cardiovasc Diabetol. 2020 Feb 12;19(1):17. (PMID: 32050968)
      Lancet. 2019 Jan 5;393(10166):31-39. (PMID: 30424892)
      Am J Cardiol. 2019 Dec 15;124 Suppl 1:S36-S44. (PMID: 31741439)
      N Engl J Med. 2013 Oct 3;369(14):1327-35. (PMID: 23992602)
      Circulation. 2018 Oct 23;138(17):1904-1907. (PMID: 30354665)
      N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602)
      BMJ. 2019 Aug 29;366:l4772. (PMID: 31467044)
      Chest. 2017 Oct;152(4):810-820. (PMID: 28427968)
      Circ J. 2013;77(8):1923-32. (PMID: 23842096)
      J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. (PMID: 29540325)
      N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
      N Engl J Med. 2013 Oct 3;369(14):1317-26. (PMID: 23992601)
      Circulation. 2011 Jul 19;124(3):314-23. (PMID: 21730306)
      N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
      BMJ Open. 2019 Mar 1;9(3):e025806. (PMID: 30826768)
      Diabetologia. 2018 Oct;61(10):2098-2107. (PMID: 30132034)
    • Grant Information:
      AstraZeneca
    • Contributed Indexing:
      Keywords: Cardiovascular event; Sodium-glucose cotransporter 2; Type 2 diabetes
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Glucose)
      0 (Dipeptidyl-Peptidase IV Inhibitors)
      0 (Glycated Hemoglobin A)
      0 (Hypoglycemic Agents)
      0 (Sodium-Glucose Transporter 2 Inhibitors)
      0 (hemoglobin A1c protein, human)
    • Publication Date:
      Date Created: 20200613 Date Completed: 20211004 Latest Revision: 20240330
    • Publication Date:
      20240330
    • Accession Number:
      PMC7779275
    • Accession Number:
      10.1111/jdi.13321
    • Accession Number:
      32530554